HOME >> BIOLOGY >> NEWS
Specific gene mutations responsible for congenital heart defects

DALLAS July 6, 2003 Researchers at UT Southwestern Medical Center at Dallas have discovered a gene critical to the development of the human heart and that mutations in the gene lead to congenital heart defects the leading noninfectious cause of death in newborns.

GATA4 is only the second gene to have been identified as a cause of isolated congenital heart disease not associated with medically identified syndromes.

The findings will be published in a future edition of the journal Nature and appear online today.

The researchers identified mutations in the gene GATA4 as a cause of human cardiac septal defects, which occur when the walls separating the heart's four chambers do not form properly.

"In terms of identifying genetic etiologies, there are not many discoveries that have been made," said Dr. Vidu Garg, assistant professor of pediatrics and one of the study's lead authors. "This is one of the genes responsible, and we are working to identify others."

This discovery could one day help doctors prevent congenital heart defects the most common developmental anomaly by fixing the problem before a baby is born, said Dr. Deepak Srivastava, associate professor of pediatrics and molecular biology and the study's senior author.

"We cannot change the fact that parents are going to pass along the mutation, but we might be able to develop a way to keep the disease from occurring," said Dr. Srivastava.

In the Nature study, researchers from UT Southwestern and three Japanese medical institutions examined two large families: one in Dallas that spanned five generations and included 16 members suffering from congenital heart defects, and a family from Tokyo spanning four generations and with eight members with congenital heart defects.

UT Southwestern researchers and Dr. Rumiko Matsuoka, a pediatric cardiologist from Japan, gathered data from the families' medical history. Researchers also condu
'"/>

Contact: Staishy Bostick Siem
staishy.siem@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
6-Jul-2003


Page: 1 2 3

Related biology news :

1. UB Researchers Identify Specific Oral Bacteria Most Likely To Increase Risk Of Heart Disease
2. Vions TAPET Organisms Demonstrate Reduced Virulence, Increased Safety While Retaining Ability To Specifically Target Tumors
3. Sex-Specific Behavior Controlled By Peripheral Nervous System
4. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
5. New Tests Demonstrate MuchLarger, More Specific Immune Responses To Viruses
6. Mouse Model Of Down Syndrome Offers Glimpse Into Role Of Specific Genes In TheDisorder
7. Novel AIDS-Directed Technology: Approach Permits Optimization Of Existing Drug Therapies And Targeted, Patient-Specific Treatment
8. Genetic mutations linked to the practice of burning coal in homes in China
9. Rare mutations can significantly increase risk factor for heart disease
10. The mother lode of mutations
11. Mastectomy dramatically reduces breast cancer risk among women with BRCA1/2 mutations

Post Your Comments:
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
(Date:4/16/2015)... MENLO PARK, Calif. , April 16, ... (DelMar and the Company), a biopharmaceutical company focused on ... drug indications, today announced that the Mayo Clinic ... trial site for the ongoing, multicenter Phase I/II study ... the most common and deadly form of human brain ...
(Date:4/16/2015)... Md. , April 16, 2015  Northwest ... a biotechnology company developing non-toxic DCVax® personalized immune ... been included in the Loncar Cancer Immunotherapy Index ... investors better track the immunotherapy field within the ... have selected "the top 25 companies" in the ...
(Date:4/16/2015)... April 16, 2015 Modality Solutions, ... systems for highly regulated industries, is pleased to ... a monthly columnist for Cold Chain IQ - ... ). His column titled, Global Cold Chain Connections, ... for today’s life sciences, pharmaceutical and healthcare supply ...
(Date:4/15/2015)... OXFORD, England , April 16, 2015 /PRNewswire/ ... company developing novel biological drugs to treat cancer ... research and development arm of AstraZeneca, today announced ... Under the terms of the agreement, ... combining MedImmune,s investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or ...
Breaking Biology Technology:DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 2Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 4Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 5Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 6
Cached News: